Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.

Warrior Met Coal, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (NYSE: HCC) (WARRIOR OR THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE THIRD QUARTER OF 2025. WARRIOR IS THE LEADING DEDICATED U.S.-BASED PRODUCER AND EXPORTER OF HIGH-QUALITY STEELMAKING COAL FOR THE GLOBAL STEEL INDUSTRY. WARRIOR REPORTED NET INCOME FOR THE THIRD QUARTER OF 2025 OF $36.6 MILLION, OR $0.70 PER DILUTED SHARE, A DECREASE FROM NET INCOME OF $41.8 MILLION, OR $0.80 PER DILUTED SHARE, IN THE THIRD QUARTER OF 2024. THE COMPA.

WARRIOR REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES OUTLOOK

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (NYSE:HCC) (WARRIOR OR THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED A REGULAR QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE TO BE PAID ON NOVEMBER 14, 2025, TO STOCKHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON NOVEMBER 7, 2025. ABOUT WARRIOR WARRIOR IS A U.S.-BASED, ENVIRONMENTALLY, AND SOCIALLY MINDED SUPPLIER TO THE GLOBAL STEEL INDUSTRY. IT IS DEDICATED ENTIRELY TO MINING NON-THERMAL METALLURGICAL (MET) CO.

WARRIOR ANNOUNCES REGULAR QUARTERLY CASH DIVIDEND

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (WARRIOR OR NYSE: HCC) TODAY ANNOUNCED THAT IT WILL HOLD ITS THIRD QUARTER 2025 INVESTOR CONFERENCE CALL AT 4:30 P.M. ET ON WEDNESDAY, NOVEMBER 5, 2025. WARRIOR WILL RELEASE ITS RESULTS FOLLOWING THE CLOSE OF MARKET TRADING THAT AFTERNOON. TO PARTICIPATE IN THE CONFERENCE CALL, PLEASE CALL 1-844-340-9047 (DOMESTIC) OR 1-412-858-5206 (INTERNATIONAL) 10 MINUTES PRIOR TO THE START TIME AND REFERENCE THE WARRIOR MET COAL CONFERENCE CALL. A.

WARRIOR SETS DATE FOR THIRD QUARTER 2025 EARNINGS ANNOUNCEMENT AND INVESTOR CONFERENCE CALL

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (NYSE: HCC) (WARRIOR OR THE COMPANY) ANNOUNCED TODAY THAT IT HAS AMENDED AND EXTENDED ITS EXISTING SECOND AMENDED AND RESTATED ASSET-BASED REVOLVING CREDIT FACILITY (AS SO AMENDED AND EXTENDED, THE AMENDED ABL FACILITY OR CREDIT FACILITY). UNDER THE AMENDED ABL FACILITY, AMONG OTHER THINGS, (I) THE AGGREGATE COMMITMENTS AVAILABLE TO BE BORROWED UNDER THE CREDIT FACILITY HAVE BEEN INCREASED BY $27.0 MILLION TO $143.0 MILLION; (II).

WARRIOR COMPLETES AMENDMENT AND EXTENSION TO ITS ASSET-BASED REVOLVING CREDIT FACILITY

HOUSTON, AUG. 20, 2025 (GLOBE NEWSWIRE) -- TOKIO MARINE HCC, BASED IN HOUSTON, TEXAS, TODAY ANNOUNCED THAT FITCH RATINGS HAS AFFIRMED THE AA-' (VERY STRONG) INSURER FINANCIAL STRENGTH (IFS) RATINGS FOR ITS INSURANCE COMPANY SUBSIDIARIES AND THE A' LONG-TERM ISSUER DEFAULT RATING FOR HCC INSURANCE HOLDINGS, INC. THE OUTLOOK FOR ALL OF FITCH'S RATINGS IS STABLE.

TOKIO MARINE HCC AA-' RATINGS AFFIRMED BY FITCH WITH STABLE OUTLOOK

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (NYSE:HCC) (WARRIOR OR THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED A REGULAR QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE TO BE PAID ON AUGUST 15, 2025, TO STOCKHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON AUGUST 8, 2025. ABOUT WARRIOR WARRIOR IS A U.S.-BASED, ENVIRONMENTALLY, AND SOCIALLY MINDED SUPPLIER TO THE GLOBAL STEEL INDUSTRY. IT IS DEDICATED ENTIRELY TO MINING NON-THERMAL METALLURGICAL (MET) COAL U.

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (WARRIOR OR NYSE: HCC) TODAY ANNOUNCED THAT IT WILL HOLD ITS SECOND QUARTER 2025 INVESTOR CONFERENCE CALL AT 4:30 P.M. ET ON WEDNESDAY, AUGUST 6, 2025. WARRIOR WILL RELEASE ITS RESULTS FOLLOWING THE CLOSE OF MARKET TRADING THAT AFTERNOON. TO PARTICIPATE IN THE CONFERENCE CALL, PLEASE CALL 1-844-340-9047 (DOMESTIC) OR 1-412-858-5206 (INTERNATIONAL) 10 MINUTES PRIOR TO THE START TIME AND REFERENCE THE WARRIOR MET COAL CONFERENCE CALL. A W.

WARRIOR SETS DATE FOR SECOND QUARTER 2025 EARNINGS ANNOUNCEMENT AND INVESTOR CONFERENCE CALL

BRISBANE, CALIF., JUNE 30, 2025 (GLOBE NEWSWIRE) -- TEMPEST THERAPEUTICS, INC. (NASDAQ: TPST), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY WITH A PIPELINE OF FIRST-IN-CLASSI TARGETED AND IMMUNE-MEDIATED THERAPEUTICS TO FIGHT CANCER, TODAY ANNOUNCED THAT THE COMPANY RECEIVED APPROVAL FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN CHINA TO PROCEED WITH A PIVOTAL TRIAL TO EVALUATE AMEZALPAT (TPST-1120) IN COMBINATION WITH ATEZOLIZUMAB AND BEVACIZUMAB, THE CURRENT STANDARD OF CARE, VERSUS THE STANDARD OF CARE ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC).

TEMPEST RECEIVES CLEARANCE TO PROCEED WITH PIVOTAL TRIAL OF AMEZALPAT COMBINATION THERAPY FOR FIRST-LINE HCC IN CHINA

EMA ORPHAN DRUG DESIGNATION (ODD) BUILDS ON U.S. FOOD & DRUG ADMINISTRATION (FDA) ODD AND FAST TRACK DESIGNATION, UNDERSCORING THE URGENT NEED FOR NEW TREATMENT OPTIONS THE MULTIPLE REGULATORY DESIGNATIONS WERE GRANTED FOLLOWING STRONG POSITIVE RESULTS FROM A GLOBAL RANDOMIZED PHASE 1B/2 STUDY IN FIRST-LINE HCC DEMONSTRATING SUPERIOR OUTCOMES FOR AMEZALPAT COMBINATION THERAPY ACROSS MULTIPLE STUDY ENDPOINTS, INCLUDING OVERALL SURVIVAL IN BOTH THE ENTIRE POPULATION AND KEY SUBPOPULATIONS, WHEN COMPARED TO STANDARD OF CARE ALONE BRISBANE, CALIF., JUNE 05, 2025 (GLOBE NEWSWIRE) -- TEMPEST THERAPEUTICS, INC. (NASDAQ: TPST), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY WITH A PIPELINE OF FIRST-IN-CLASS1 TARGETED AND IMMUNE-MEDIATED THERAPEUTICS TO FIGHT CANCER, TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION (ODD) TO AMEZALPAT (TPST-1120), AN ORAL, SMALL MOLECULE, SELECTIVE PPAR ANTAGONIST FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC).

TEMPEST RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR AMEZALPAT FOR THE TREATMENT OF PATIENTS WITH HCC

THIS CAMPAIGN AIMS TO RAISE AWARENESS OF THE HIGH-QUALITY CARE AND SERVICES PROVIDED BY SUSAN G. KOMEN TO IMPROVE AND SAVE THE LIVES OF THOSE IMPACTED BY BREAST CANCER THIS CAMPAIGN AIMS TO RAISE AWARENESS OF THE HIGH-QUALITY CARE AND SERVICES PROVIDED BY SUSAN G. KOMEN TO IMPROVE AND SAVE THE LIVES OF THOSE IMPACTED BY BREAST CANCER

Warrior Met Coal, Inc.

HCC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Warrior Met Coal, Inc.

HCC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HCC